Revenue
2019
2020
2021
2022
2023
2024
2025
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $158.3M | $14.0M | $17.5M | $15.9M | $12.9M | $739,628 | $8.1M |
| Gross profit | $145.1M | $8.1M | $14.6M | $13.1M | $9.8M | $501,916 | — |
| Gross margin | 91.64% | 58.00% | 83.49% | 82.06% | 76.48% | 67.86% | — |
| Research & development | $39.3M | $47.8M | $43.2M | $19.4M | $20.5M | $32.2M | $40.5M |
| Operating expenses | $209.7M | $135.3M | $90.9M | $54.7M | $46.6M | $59.8M | $54.9M |
| Operating income | −$51.4M | −$121.3M | −$73.4M | −$38.8M | −$33.8M | −$59.1M | −$46.8M |
| Operating margin | −32.45% | −866.63% | −419.62% | −243.30% | −262.95% | −7,989.03% | −580.07% |
| EBITDA | −$49.8M | −$119.1M | −$71.2M | −$35.1M | −$28.2M | −$56.0M | −$44.3M |
| EBITDA margin | −31.49% | −850.94% | −407.17% | −220.41% | −219.29% | −7,565.90% | −548.26% |
| Net income | −$68.9M | −$128.3M | −$78.5M | −$41.0M | −$34.6M | −$59.8M | −$47.6M |
| Net profit margin | −43.53% | −916.63% | −448.89% | −257.39% | −269.03% | −8,080.11% | −589.48% |
| Basic EPSper basic share | -$0.80 | -$1.63 | -$1.21 | -$0.67 | -$0.70 | -$1.76 | -$2.57 |
| Diluted EPSper diluted share | -$0.80 | -$1.63 | -$1.21 | -$0.67 | -$0.70 | -$1.76 | -$2.57 |
Reported shareholders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 12.11%10.79M shares |
FARALLON CAPITAL MANAGEMENT, L.L.C. | 9.39%8.37M shares |
Caligan Partners LP | 9.11%8.12M shares |
FINDELL CAPITAL MANAGEMENT LLC | 3.93%3.5M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.52%3.14M shares |
STATE STREET CORP | 3.40%3.03M shares |
Opaleye Management Inc. | 2.75%2.45M shares |
JEFFS ROGER | ≈2.50%2.23M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.38%2.12M shares |
BANK OF AMERICA CORP /DE/ | 2.24%1.99M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 2.18%1.94M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 1.72%1.53M shares |
Caprock Group, LLC | 1.58%1.41M shares |
MPM BIOIMPACT LLC | 1.56%1.39M shares |
D. E. Shaw & Co., Inc. | 1.42%1.27M shares |
FULLER & THALER ASSET MANAGEMENT, INC. | 1.36%1.21M shares |
GOLDMAN SACHS GROUP INC | 1.08%958.89K shares |
Bloch Stephen M | ≈1.07%951.67K shares |
FEDERATED HERMES, INC. | 0.92%816.19K shares |
NORTHERN TRUST CORP | 0.80%709.06K shares |
Percentages use 89.1M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 22, 2026Form 4 | Bloch Stephen MDirector | SellCommon Stock · indirect | 30.5K | $76.18 | $2.32M | 880.1K |
| Jun 22, 2026Form 4 | Bloch Stephen MDirector | SellCommon Stock · indirect | 69.5K | $75.54 | $5.25M | 910.6K |
| Jun 15, 2026Form 4 | Bloch Stephen MDirector | SellCommon Stock · indirect | 2.3K | $72.08 | $167.4K | 980.1K |
| Jun 15, 2026Form 4 | Bloch Stephen MDirector | SellCommon Stock · indirect | 82.7K | $71.42 | $5.91M | 982.4K |
| Jun 12, 2026Form 4 | Bloch Stephen MDirector | SellCommon Stock · indirect | 13.1K | $72.15 | $944.8K | 1.07M |
A Delaware federal court found two claims of US patent 11,826,327, held by United Therapeutics ($UTHR), valid and infringed in its litigation against Liquidia ($LQDA). Four other asserted claims were held invalid. The patent concerns inhale ...